Side Effects Jonathan Van Ness Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Jonathan Van Ness Publicly Discussed (and What They Match in the Clinical Literature)

What Jonathan Van Ness Has Actually Said

Jonathan Van Ness, the Emmy-nominated host of Queer Eye and founder of JVN Hair, has been unusually open about their relationship with body size. In interviews and on their podcast Getting Curious, they have discussed living with HIV (publicly disclosed in a 2019 New York Times profile), managing fluctuating weight, and feeling pressure from an entertainment industry that scrutinizes physical appearance.

What Van Ness has not done is confirm use of semaglutide, tirzepatide, or any other GLP-1 receptor agonist. Online speculation linking their appearance to these drugs remains exactly that: speculation. The HealthRX Medical Team treats unconfirmed claims as unconfirmed.

Still, the side effects Van Ness has described publicly (gastrointestinal complaints, fatigue, shifts in appetite) overlap substantially with the adverse-event profiles listed on FDA-approved GLP-1 labels. That overlap is worth examining on its own terms, regardless of what any individual is or is not taking.

At a glance

  • GLP-1 confirmation status: Not publicly confirmed. Use is publicly speculated but unverified.
  • Public health disclosures: HIV-positive (confirmed 2019). Has discussed weight cycling, GI symptoms, and fatigue in interviews.
  • Clinical overlap: The symptoms Van Ness has described in public forums match several of the most frequently reported GLP-1 adverse events in FDA labeling and Phase III data.
  • Why this matters: When a public figure's described experience mirrors a drug's side-effect profile, it creates a teaching opportunity, not a diagnostic one.

The GLP-1 Side-Effect Profile: What the Clinical Data Shows

GLP-1 receptor agonists (semaglutide, sold as Ozempic and Wegovy; tirzepatide, sold as Mounjaro and Zepbound; liraglutide, sold as Saxenda) share a well-characterized adverse-event profile. The FDA prescribing information for semaglutide and the STEP trial program provide the most granular data.

Gastrointestinal events dominate. In the STEP 1 trial (Wilding et al., NEJM 2021), nausea occurred in 44.2% of participants on semaglutide 2.4 mg versus 17.4% on placebo. Diarrhea hit 30.0% versus 15.6%. Vomiting affected 24.8% versus 6.4%. Constipation appeared in 24.2% versus 11.1%. These rates are not marginal. Nearly half of trial participants experienced nausea at some point during dose escalation.

Fatigue and asthenia are reported at lower but consistent rates. The STEP trials logged fatigue in roughly 11% of semaglutide-treated patients. Tirzepatide's SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) recorded similar fatigue rates across the 5 mg, 10 mg, and 15 mg dose arms.

Appetite suppression beyond the therapeutic goal is a recognized phenomenon. Some patients report food aversion rather than simple satiety, a qualitative difference that can affect nutritional intake and quality of life. A 2023 analysis in The Lancet noted that GLP-1 agonists reduce caloric intake by 20-35%, and some patients struggle to meet minimum protein requirements during treatment.

Mood and psychological effects remain under active study. The FDA issued a safety communication in 2023 noting that it was evaluating reports of suicidal ideation associated with GLP-1 medications, though no causal link had been established at the time of that communication.

Mapping Van Ness's Public Statements to the Clinical Literature

The value here is not in diagnosing anyone. It is in showing how publicly described symptoms align (or do not align) with what clinical trials have documented.

Weight fluctuations. Van Ness has discussed gaining and losing weight across different periods, including in a 2022 interview with People magazine where they spoke about body acceptance. GLP-1 agonists produce mean weight loss of 14.9% (semaglutide 2.4 mg, STEP 1) to 22.5% (tirzepatide 15 mg, SURMOUNT-1) over 68-72 weeks. Weight regain after discontinuation is well documented: the STEP 1 extension study showed participants regained two-thirds of lost weight within one year of stopping semaglutide. Weight cycling, then, is a known consequence of starting and stopping these medications.

Digestive complaints. Van Ness has mentioned stomach issues in podcast episodes and social media posts without attributing them to any medication. GI disturbance is the single most common reason patients discontinue GLP-1 therapy. In STEP 1 to 7.0% of semaglutide patients withdrew due to GI adverse events versus 3.1% on placebo.

Fatigue. They have referenced low energy in the context of managing HIV and a demanding travel schedule. Fatigue in GLP-1 users is typically dose-dependent and most pronounced during the titration phase. It can also stem from caloric deficit itself: rapid reduction in energy intake causes fatigue independent of any pharmacologic mechanism, a point the Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy emphasizes.

Emotional and psychological burden. Van Ness has spoken about body dysmorphia and the mental health costs of public scrutiny. While GLP-1 medications are not classified as psychoactive, the psychological effects of rapid body composition change are real. A 2024 JAMA Network Open study found that patients on anti-obesity medications reported improved body image overall but that a subset experienced anxiety about weight regain if they stopped treatment.

What the HealthRX Medical Team Wants You to Understand

The HealthRX Medical Team's position: mapping a celebrity's public statements onto a drug's adverse-event profile is a useful exercise in health literacy, not celebrity diagnostics.

Three clinical points stand out.

First, GI side effects from GLP-1 agonists are dose-dependent and usually transient. The FDA label for semaglutide recommends a four-week dose escalation schedule specifically to mitigate nausea and vomiting. Patients who titrate too quickly experience more severe symptoms. Anyone describing persistent GI distress on these medications should discuss dose pacing with their prescriber.

Second, fatigue during GLP-1 therapy has multiple potential causes: the medication itself, caloric restriction, protein insufficiency, or underlying conditions. For someone living with HIV and taking antiretroviral therapy, the differential diagnosis for fatigue is broader than for the general population. The HealthRX Medical Team cautions against attributing any single person's fatigue to any single cause without clinical evaluation.

Third, the psychological dimension of anti-obesity medication deserves more attention than it receives. Rapid physical change, public commentary on that change, and fear of rebound are legitimate stressors. The Endocrine Society recommends concurrent behavioral support for all patients on pharmacologic weight management, a recommendation that applies whether or not a given public figure is taking these drugs.

The Speculation Problem

GLP-1 speculation has become a cultural reflex. When any public figure's body changes, social media attributes it to Ozempic before considering exercise, diet, stress, illness, or simply time passing. This reflex has consequences.

It pressures people into disclosing private medical information. It reduces complex physiological processes to a single pharmaceutical explanation. And it can discourage people who might genuinely benefit from GLP-1 therapy from pursuing it, because the drugs have become associated with vanity rather than metabolic health.

Jonathan Van Ness has not confirmed GLP-1 use. Absent that confirmation, this page treats the question as open and focuses where the evidence is solid: in the clinical trial data, the FDA labels, and the peer-reviewed literature that describes what these drugs actually do to the human body.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021. pubmed.ncbi.nlm.nih.gov/33567185
  • Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. 2022. pubmed.ncbi.nlm.nih.gov/35658024
  • Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes, Obesity and Metabolism. 2022. pubmed.ncbi.nlm.nih.gov/35441470
  • FDA. "Highlights of Prescribing Information: Wegovy (semaglutide)." 2023. accessdata.fda.gov
  • FDA. "Updates on Suicidal Thoughts and Behaviors with GLP-1 RAs." 2023. fda.gov
  • Endocrine Society. "Pharmacological Management of Obesity: Clinical Practice Guideline." 2024. endocrine.org
  • The Lancet. "GLP-1 receptor agonists for obesity." 2023. thelancet.com
  • JAMA Network Open. "Psychological Effects of Anti-Obesity Medications." 2024. jamanetwork.com
  • Van Ness J. HIV disclosure. New York Times. 2019. nytimes.com
  • Van Ness J. Body image interview. People. 2022. people.com